Clinical Trial Update: A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dose-response, efficacy (immunogenicity) and safety of GC1109 for anthrax has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax

Drugs mentioned

• GC1109

Snippet

Sponsor: Green Cross Corporation | Conditions: Anthrax | Phase 2 | Status: COMPLETED